Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Sponsor: David Peereboom
Listed as NCT03452579, this PHASE2 trial focuses on Glioblastoma and remains ongoing. Sponsored by David Peereboom, it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Mar 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 8 earlier versions
-
Feb 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Feb 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- David Peereboom
For direct contact, visit the study record on ClinicalTrials.gov .